Inhibikase Therapeutics Inc (IKT)

Date: O: H: L: C: Vol:

Finanzdaten der Inhibikase Therapeutics Inc-Aktie (IKT)

*Alle Zahlen in Millionen

Enddatum des Zeitraums	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30
Periodenlänge	3 Monate	3 Monate	3 Monate	3 Monate	3 Monate
Revenues	-	-	-	-	-
	3.82%7.66	7.38	6.77	5.61	5.92
Selling, General, and Administrative	3.82%7.66	7.38	6.77	5.61	5.92
Research and Development	23.57%13.39	10.84	6.36	7.65	5.27
Costs And Expenses	17.99%21.05	17.84	13.78	12.77	10.83
Operating Income/Loss	17.99%-21.05	-17.84	-13.78	-12.77	-10.83
Net Interest Income/Expense	0.09%1.46	1.46	1.04	0.84	0.92
Income Tax Expense/Benefit	-	-	-	-	-
	19.60%-19.59	-16.38	-12.73	-11.93	-9.92
Attributable To Parent	19.60%-19.59	-16.38	-12.73	-11.93	-9.92
Basic Average Shares	1.31%174.57	172.31	-	90.05	90.01
Diluted Average Shares	1.31%174.57	172.31	-	90.05	90.01
Basic Earnings Per Share	10.00%-0.11	-0.10	-	-0.13	-0.11
Diluted Earnings Per Share	10.00%-0.11	-0.10	-	-0.13	-0.11